For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Regulus Therapeutics Inc.

USPTO Granted Patents = 61

CIPO Patents = 1

EPO Patents = 11

Trademarks = 4

Forward Citations = 610

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

C Frank Bennett (27 out of 202 patents)

Balkrishen Bhat (27 out of 80 patents)

Susan M Freier (21 out of 254 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

6. Christine Esau (11 out of 14 patents)

7. B Nelson Chau (6 out of 6 patents)

8. Noga Yerushalmi (6 out of 10 patents)

9. Ravi Jain (6 out of 22 patents)

10. Ayelet Chajut (6 out of 8 patents)

11. Bridget Lollo (6 out of 6 patents)

12. Daniel J Hogan (4 out of 5 patents)

13. Jeremy Duffield (4 out of 6 patents)

14. Eric E Swayze (4 out of 201 patents)

15. Deidre A MacKenna (4 out of 7 patents)

Core Competencies:

MicroRNA Compounds

Oligomeric Compounds

Polycystic Kidney Disease

HCV Antiviral Activity

Liver Cancer Treatment

Metabolic Disorders

Small Non-Coding RNAs

Alport Syndrome

Fibrosis Treatment

Cellular Uptake Enhancement

miR-122 Modulation

miR-21 Activity

61 patents: Sort by Forward Citations

1. 12005120 - Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect (2024-06-11),

2. 11168325 - Methods for treatment of polycystic kidney disease (2021-11-09),

3. 10941400 - Compounds and methods for enhanced cellular uptake (2021-03-09),

4. 10633657 - Methods for treatment of polycystic kidney disease (2020-04-28),

5. 10584336 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2020-03-10),

6. 10301627 - Targeting microRNAs for the treatment of liver cancer (2019-05-28),

7. 10240151 - Compounds and methods for enhanced cellular uptake (2019-03-26),

8. 10150967 - MicroRNA compounds and methods for modulating miR-122 (2018-12-11),

9. 10138484 - Targeting microRNAs for metabolic disorders (2018-11-27),

10. 10093926 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-10-09),

11. 10072265 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-09-11),

12. 9994846 - MicroRNA compounds and methods for modulating miR-21 activity (2018-06-12),

13. 9994842 - Methods for use in modulating miR-122A (2018-06-12),

14. 9970011 - Methods for treatment of alport syndrome (2018-05-15),

15. 9970009 - MicroRNA compounds and methods for modulating miR-21 activity (2018-05-15),

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs to treat a range of diseases. The company utilizes its proprietary oligonucleotide technologies to modify the activity of microRNAs, which are key regulators of gene expression.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

61 Patents

#103 in San Diego, CA

#1,348 in California

#5,713 in US

#11,505 in the World

San Diego, CA, United States of America

Regulus Therapeutics Inc.

Forward Citations = 610

34 inventors:

C Frank Bennett (27 out of 202 patents)

Balkrishen Bhat (27 out of 80 patents)

Susan M Freier (21 out of 254 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

Please report any incorrect information to support@idiyas.com

Loading…